Aegerion Pharmaceuticals, Inc. (AEGR): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report


Shutterstock photo

Aegerion reported a loss of $0.20 per share in the third-quarter of 2014, wider than the Zacks Consensus Estimate for a loss of only $0.18 but narrower than the year-ago loss of $0.43. Revenues of $43.7 million missed the Zacks Consensus Estimate of $49 million. We are disappointed with the company's lowered outlook for Juxtapid sales this year. Additionally, the 2015 revenue outlook lags growth expectations significantly. With Aegerion depending on Juxtapid for growth, reimbursement issues and potential competition remain matters of concern. We are remaining on the sidelines and maintaining a Neutral recommendation on Aegerion.


Cambridge, MA-based Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of innovative treatments for rare diseases.

Juxtapid (EU trade name: Lojuxta), Aegerion's only marketed product, received FDA approval in Dec 2012 for the treatment of homozygous familial hypercholesterolemia (HoFH). Aegerion is also conducting a late-stage development program for the geographical expansion of Juxtapid.

Juxtapid is approved in the U.S., the EU, Mexico, Canada, Norway and Iceland. Aegerion generated net revenues of $48.5 million in 2013 consisting of Juxtapid sales.

Aegerion Pharmaceuticals, Inc. (AEGR): Read the Full Research Report
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AEGERION PHARMA (AEGR): Free Stock Analysis Report

To read this article on click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Stocks

More from


Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by